FDA Approval Summary: Tocilizumab for Treatment of Chimeric Antigen Receptor T Cell-Induced Severe or Life-Threatening Cytokine Release Syndrome

Oncologist

Volumn 23, Issue 8, 2018, Pages 943-947

  Le, Robert Q ^a   Li, Liang ^a   Yuan, Weishi ^a   Shord, Stacy S ^a   Nie, Lei ^a   Habtemariam, Bahru A ^a   Przepiorka, Donna ^a   Farrell, Ann T ^a   Pazdur, Richard ^a,b  

^a Center for Drug Evaluation and Research   (United States)

^b CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

Author keywords

Chimeric antigen receptor; Cytokine release syndrome; Immunotherapy; Interleukin 6; T cell; Tocilizumab

Indexed keywords

AXICABTAGENE CILOLEUCEL; CHIMERIC ANTIGEN RECEPTOR; TISAGENLECLEUCEL T; TOCILIZUMAB; CYTOKINE; LYMPHOCYTE ANTIGEN RECEPTOR; MONOCLONAL ANTIBODY;

ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; ARTICLE; CHILD; CLINICAL TRIAL (TOPIC); COHORT ANALYSIS; COMPARATIVE STUDY; CYTOKINE RELEASE SYNDROME; DIFFUSE LARGE B CELL LYMPHOMA; DISEASE SEVERITY; DRUG APPROVAL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG RESPONSE; DRUG SAFETY; FEMALE; FOOD AND DRUG ADMINISTRATION; HUMAN; MAJOR CLINICAL STUDY; MALE; PHARMACOKINETIC PARAMETERS; PRIORITY JOURNAL; REPEATED DRUG DOSE; RETROSPECTIVE STUDY; SINGLE DRUG DOSE; SYSTEMIC JUVENILE IDIOPATHIC ARTHRITIS; TREATMENT DURATION; VOLUME OF DISTRIBUTION; YOUNG ADULT; IMMUNOLOGY; METABOLISM; PRESCHOOL CHILD; PROSPECTIVE STUDY; SYNDROME; UNITED STATES;

ADOLESCENT; ADULT; ANTIBODIES, MONOCLONAL, HUMANIZED; CHILD; CHILD, PRESCHOOL; CYTOKINES; FEMALE; HUMANS; MALE; PROSPECTIVE STUDIES; RECEPTORS, ANTIGEN, T-CELL; RECEPTORS, CHIMERIC ANTIGEN; RETROSPECTIVE STUDIES; SYNDROME; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION; YOUNG ADULT;

EID: 85045111924     PISSN: 10837159     EISSN: 1549490X     Source Type: Journal    
DOI: 10.1634/theoncologist.2018-0028     Document Type: Article

References (20)

1. Morgan RA, Yang JC, Kitano M et al. Case report of a serious adverse event following the administration of T cells transduced with a chimeric antigen receptor recognizing ERBB2. Mol Ther 2010;18:843–851
2. Fitzgerald JC, Weiss SL, Maude SL et al. Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia. Crit Care Med 2017;45:e124–e131
3. Brentjens RJ, Davila ML, Riviere I et al. CD19-targeted T cells rapidly induce molecular remissions in adults with chemotherapy-refractory acute lymphoblastic leukemia. Sci Transl Med 2013;5:177ra38
4. Lee DW, Gardner R, Porter DL et al. Current concepts in the diagnosis and management of cytokine release syndrome. Blood 2014;124:188–195
5. Brudno JN, Kochenderfer JN. Toxicities of chimeric antigen receptor T cells: Recognition and management. Blood 2016;127:3321–3330
6. Frey NV, Porter DL. Cytokine release syndrome with novel therapeutics for acute lymphoblastic leukemia. Hematology Am Soc Hematol Educ Program 2016;2016:567–2072
7. Kalos M, Levine BL, Porter DL et al. T cells with chimeric antigen receptors have potent antitumor effects and can establish memory in patients with advanced leukemia. Sci Transl Med 2011;3:95ra73
8. Teachey DT, Lacey SF, Shaw PA et al. Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia. Cancer Discov 2016;6:664–679
9. Kochenderfer JN, Dudley ME, Feldman SA et al. B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells. Blood 2012;119:2709–2720
10. Porter DL, Hwang WT, Frey NV et al. Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia. Sci Transl Med 2015;7:303ra139
11. Davila ML, Riviere I, Wang X et al. Efficacy and toxicity management of 19-28z CAR T cell therapy in B cell acute lymphoblastic leukemia. Sci Transl Med 2014;6:224ra25
12. Grupp SA, Kalos M, Barrett D et al. Chimeric antigen receptor-modified T cells for acute lymphoid leukemia. N Engl J Med 2013;368:1509–1518
13. Kochendorfer JN, Dudley ME, Kassim SH et al. Chemotherapy-refractory diffuse large B-cell lymphoma and indolent B-cell malignancies can be effectively treated with autologous T cells expressing an anti-CD19 chimeric antigen receptor. J Clin Oncol 2015;33:540–549
14. Maude SL, Frey N, Shaw PA et al. Chimeric antigen receptor T cells for sustained remissions in leukemia. N Engl J Med 2014;371:1507–1517
15. Lee Dw, Kochendorfer JN, Stetler-Stevenson M et al. T cells expressing CD19 chimeric antigen receptors for acute lymphoblastic leukaemia in children and young adults: A phase 1 dose-escalation trial. Lancet 2015;385:517–528
16. Luo Y, Chang LJ, Hu Y et al. First-in-man CD123-specific chimeric antigen receptor-modified T cells for the treatment of refractory acute myeloid leukemia. Blood 2015;126:3778A
17. Tanyi JL, Stashwick C, Plesa G et al. Possible compartmental cytokine release syndrome in a patient with recurrent ovarian cancer after treatment with mesothelin-targeted CAR-T cells. J Immunother 2017;40:104–107
18. Frey NV, Levine BL, Lacey SF et al. Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells. Blood 2014;124:2296A
19. Grange S, Schmitt C, Banken L et al. Thorough QT/QTc study of tocilizumab after single-dose administration at therapeutic and supratherapeutic doses in healthy subjects. Int J Clin Pharmacol Ther 2011:49:648–655
20. Shovman O, Shoenfeld Y, Langevitz P. Tocilizumab-induced neutropenia in rheumatoid arthritis patients with previous history of neutropenia: Case series and review of literature. Immunol Res 2015;61:164–168